TEM · Tempus AI, Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|
| $1.6B – $1.61B | $1.43B | $1.27B | $693.4M | $531.82M | $320.67M | |
| — | $196.31M | $172.92M | $149.33M | $90.34M | $83.16M | |
| — | $834.84M | $731.74M | $755.35M | $296.76M | $233.38M | |
| — | $1.72B | $1.52B | $1.38B | $727.91M | $586.11M | |
| — | -$283.03M | -$252.87M | -$691.08M | -$196.08M | -$265.44M | |
| — | — | -19.88% | -99.67% | -36.87% | -82.78% | |
| — | $17.49M | $12.63M | $11.08M | $7.6M | $3.03M | |
| — | $92.22M | $31.45M | $32.34M | $21.82M | -$4.85M | |
| — | -$7.58M | -$5.61M | -$4.23M | -$301K | -$595K | |
| — | -$252.31M | -$291.1M | -$701.32M | -$213.53M | -$289.15M | |
| — | -$5.47M | -$51.68M | $266K | $288K | $66K | |
| — | -$254.43M | -$245.03M | -$705.81M | -$214.12M | -$289.81M | |
| — | — | -19.27% | -101.79% | -40.26% | -90.38% | |
| — | — | -$245.03M | -$746.33M | -$265.96M | -$333.93M | |
| — | -$264.81M | -$244.22M | -$705.72M | -$214.13M | -$289.78M | |
| USD/shares | — | -$1.43 | -$1.41 | -$6.23 | -$4.20 | -$5.30 |
| USD/shares | — | -$1.44 | -$1.41 | -$6.23 | -$4.20 | -$5.30 |
| shares | — | — | 174.26K | 119.85K | 63.31K | 63.31K |
| shares | — | — | 174.26K | 119.85K | 63.31K | 63.03K |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2025: $16.88M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 13 similar-size Health Information Services companies (of 46 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Diagnostics | $955,381,000 | — | — | — |
| Data and Applications | $316,408,000 | — | — | — |
| Insights Product | $257,700,000 | $186,800,000 | $117,600,000 | $88,400,000 |
| Trials Product | $38,500,000 | $42,400,000 | $45,600,000 | $31,200,000 |
| AI Applications | $20,100,000 | $12,300,000 | $5,100,000 | — |
| Data and Services | — | — | — | $122,684,000 |
| Genomic | — | — | — | $197,984,000 |
| Genomics Product | — | $451,700,000 | $363,000,000 | $198,000,000 |